Medpace (NASDAQ:MEDP) CEO Sells $403,175.50 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 650 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the sale, the chief executive officer directly owned 539,894 shares in the company, valued at $334,880,051.38. This represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Medpace Price Performance

MEDP opened at $593.02 on Thursday. The company has a market capitalization of $16.55 billion, a price-to-earnings ratio of 34.76, a P/E/G ratio of 2.60 and a beta of 1.15. The business’s 50-day moving average price is $571.91 and its two-hundred day moving average price is $497.71. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MEDP. Johnson Financial Group Inc. bought a new stake in Medpace in the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Elyxium Wealth LLC bought a new position in shares of Medpace in the fourth quarter valued at about $30,000. Jones Financial Companies Lllp acquired a new stake in shares of Medpace during the 2nd quarter worth about $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter worth about $31,000. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on MEDP shares. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. BMO Capital Markets upped their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Finally, Truist Financial increased their price objective on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $595.20.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.